UNSPSC 51382303: Feclobuzone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C27H25ClN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R6889JIL5D, chemically known as 4-chlorbenzoesaeure ester mil 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-3,5-pyrazolidindion but generally known as feclobuzone, which bears US NIH Compound Identifier 176165. European Medicines Agency schedules Feclobuzone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07523MIG.

UNSPSC 51382303 Feclobuzone is a Commodity code assigned to a recent state-local opportunity that diverges significantly from its nominal pharmaceutical scope. Seminole County, Florida posted IFB60459723LAS in June 2026 seeking to procure naloxone and safe drug deactivation systems—products unrelated to feclobuzone, a veterinary anti-inflammatory agent. The opportunity calls for 1,900 units of naloxone and 800 safe drug deactivation systems delivered annually on a quarterly basis to the Seminole County Community Health Building in Sanford, Florida, with an initial two-year contract term and one-year renewal option. Bidders must submit costs electronically, provide unit pricing for each line item, comply with drug-free workplace and E-Verify requirements, and maintain workers' compensation, commercial general liability, and professional liability insurance. The contract includes a three-month probationary period during which Seminole County may terminate with or without cause, and potential FEMA funding introduces additional federal compliance obligations including adherence to the Clean Air Act and Federal Water Pollution Control Act.

The code shows limited recent activity; only one state-local opportunity appears in the dataset, and that opportunity is tagged to feclobuzone despite procuring naloxone and harm-reduction equipment. Seminole County is the sole issuing body present, and the July 26, 2023 response deadline listed in the solicitation predates the current date. The mismatch between the code's pharmaceutical classification and the actual products being bought—coupled to sparse and outdated sourcing activity—signals that this code does not reflect current state and local procurement patterns and warrants close attention to scope classification before pursuing opportunities tagged to it.